---
document_datetime: 2025-09-24 11:36:32
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/korjuny-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: korjuny-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 5.4955439
conversion_datetime: 2025-12-19 05:20:26.186675
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## Korjuny

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency' s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessmenthistory'section.Forthe completeproduct lifecycleprocedures,you mayneedtoalsorefertoEPAR-Proceduralsteps taken andscientific information after authorisation (archive).

| Applicationnumber    | Scope                               | Opinion/ Notification 1 issued on   | Commission Decision IssuedÂ²/ amendedon   | Product Information affected3   | Summary   |
|----------------------|-------------------------------------|-------------------------------------|------------------------------------------|---------------------------------|-----------|
| Variation typeIA_IN/ | B.II.b.2.cReplacementor additionofa | 23/09/2025                          |                                          | Annex II and                    |           |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions areissuedforallotherprocedures.

3SmPC(Summary ofProductCharacteristics),AnnexII,Labelling,PL(PackageLeaflet).

2 A Commission decision(CD) is issued for procedures that affect the terms of the marketing authorisation(e.g.summary of product characteristics, annexII, labelling,package leaflet).The CDisissuedwithintwomonths of the opinionforvariationsfallingunderthescope ofArticle23.1a(a)ofRegulation(EU)No.712/2012,orwithinoneyearforotherprocedures.

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                     | manufacturerresponsibleforimportation and/or batch release - B.1I.b.2.c.1 Not includingbatchcontrol/testing-Accepted                                                                                                                                                                                                                                                                                                                             |            |     | PL   | EMA/VR/0000297256                        |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------|------------------------------------------|
|                     | B.1I1.b.1 Replacement or addition of a manufacturingsiteforpartor allofthe manufacturingprocessofthefinished product - B.1I1.b.1.a Secondary packaging site - Accepted                                                                                                                                                                                                                                                                           | 30/07/2025 | N/A |      | Variation type IA_IN / EMA/VR/0000287504 |
| VariationtypeIB/    | B.II.d.2 Change in test procedure for the finished product-B.II.d.2.z Other changes- Accepted                                                                                                                                                                                                                                                                                                                                                    | 15/07/2025 | N/A |      | EMA/VR/0000281784                        |
| Variation type IB / | This was an application for a group of variations. B.I.a.4 Change to in-process tests or limits applied during the manufacture of the active substance - B.I.a.4.c Deletion of a non- significant in-process test-Accepted B.I.a.2 Changes in the manufacturing process of the active substance - B.I.a.2.z Other variation - Accepted B.I.a.2 Changes in the manufacturing process of the active substance - B.I.a.2.z Other variation-Accepted | 26/06/2025 | N/A |      | EMA/VR/0000278207                        |

<div style=\"page-break-after: always\"></div>

| Variation type IB / EMA/VR/0000276239                   | B.1.b.2Changeintestprocedurefor active substance or starting material/reagent/intermediateused in the manufacturingprocessoftheactive substance -B.I.b.2.z Other changes - Accepted                                     | 23/06/2025   | N/A        |                        |                                                                                                                                                  |
|---------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation typeIB/ EMA/VR/0000276206                     | B.II.f.1.bExtensionoftheshelf lifeof the finishedproduct-B.II.f.1.b.5Extension of the shelf-life of a biological/ immunological medicinal product in accordancewith an approved stability protocol-Accepted             | 23/06/2025   |            | SmPC                   |                                                                                                                                                  |
| Marketing Authorisation Transfer - H / EMA/T/0000258313 | - Transfer of a marketing authorisation - transferofmarketingauthorisationfrom LindisBiotechGmbHtoAtnahsPharma Netherlands B.V.                                                                                         | 28/03/2025   | 15/05/2025 | SmPC, Labelling and PL |                                                                                                                                                  |
| Variation typeIA_IN / EMA/VR/0000255947                 | C.IHUMANANDVETERINARYMEDICINAL PRODUCTS-C.I.12Inclusion or deletion of blacksymbolandexplanatorystatementsfor medicinal products in the list of medicinal products that are subject to additional monitoring - Accepted | 26/03/2025   | 15/05/2025 | SmPC and PL            | To include in theProduct Information theblack symbol and explanatory statement for medicinal products that are subject to additional monitoring. |